Bannerbild German Brest Group

November 2018: Exploratory analysis on obese breast cancer patients from the PANTHER trial


Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.

An exploratory analysis of tailored dosing in the PANTHER trial demonstrated that obese patients (BMI≥30) treated with tailored dose-dense chemotherapy had improved breast cancer relapse-free survival (BCRFS) compared to non-obese ones (BMI<30) (HR = 0.51 [95% CI 0.30-0.89]; p=0.02). Furthermore, the tailored dose-dense chemotherapy was associated with improved BCRFS compared to standard anthracycline/taxane containing regimen only in obese patients (HR=0.49 [95%CI 0.26-0.90]; p=0.022, test for interaction p=0.175). There were no differences in terms of toxicity between the BMI groups. Hence, the use of tailored dose-dense regimen as adjuvant chemotherapy can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies.

Matikas A, Foukakis T, Moebus V, Greil R, Bengtsson NO, Steger GG, Untch M, Johansson H, Hellström M, Malmström P, Gnant M, Loibl S, Bergh J. Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. Ann Oncol. 2018 Oct 24 [Epub ahead of print].

Link in PubMed


  • 17.12.2018 Results of an interim analysis from KATHERINE trial

    We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.

    Mehr ...
  • 29.11.2018 GBG Research at SABCS

    Data of several GBG trials and translational research projects will be presented at the upcoming SABCS 2018 Congress, which will take place from 4-8 December in San Antonio, Texas, USA.

    Mehr ...
  • 11.10.2018 BIG newsletter no 9 is out

    We’re delighted to announce that the BIG newsletter BIG Research in Focus, Issue 9 is out and has been published on BIG’s website.

    Mehr ...
  • 27.09.2018 GBG-Jahrestreffen - Save the Date

    GBG-Jahrestreffen - Save the Date

    Das GBG Jahrestreffen 2019 wird am 14. & 15. März 2019 in Niederrad Frankfurt am Main stattfinden.

    Mehr ...
  • 27.09.2018 Paper of the month: models for pCR

    Paper of the month: models for pCR

    A statistical research study that aimed to develop an empirical model for predicting the magnitude of the treatment effects on survival endpoints based on the treatment effects on pathological complete response (pCR) has been published in the Contemporary Clinical Trials.

    Mehr ...

GBG Forschungs GmbH
Martin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd